| Molecular formula | C17H23N7O5 |
|---|
| Molecular weight | 405.4 g/mol |
|---|
| Registered trials | 1 |
|---|
| PubChem CID | 114750 |
|---|
What taltirelin is
Taltirelin is a synthetic compound identified by PubChem CID 114750, with the molecular formula C17H23N7O5. It has no FDA-approved label in the data reviewed here, and it is classified as unapproved for research purposes in this context. Because no label exists, this monograph cannot describe an approved mechanism, indication, or dosing.
Trial footprint
One registered trial appears in the available data. A completed Phase 4 study, "C-Trelin Orally Disintegrated (OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration" (NCT04107740), is listed in this dataset. Beyond this single record, no broader trial count or additional study details are provided here.
FAQ
No, taltirelin does not have an approved FDA label in the data reviewed here. It is treated as an investigational, unapproved research compound in this context.
Taltirelin is registered in PubChem under CID 114750, with the molecular formula C17H23N7O5 and a molecular weight of about 405.4. This identifier can be used to look up further chemical detail independently.
One trial appears in the available data: a completed Phase 4 study of an orally disintegrating tablet formulation in patients with ataxia due to spinocerebellar degeneration (NCT04107740). No additional trial count or outcome data is included in this dataset.
No adverse event report data is available in this dataset, so no side effect summary can be provided here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 114750 ClinicalTrials.gov NCT04107740
Updated 2026-09-19